133 related articles for article (PubMed ID: 34376803)
1. Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
Tadmor T; Benjamini O; Braester A; Rahav G; Rokach L
Leukemia; 2021 Sep; 35(9):2727-2730. PubMed ID: 34376803
[No Abstract] [Full Text] [Related]
2. COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
Del Poeta G; Bomben R; Polesel J; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Postorino M; Laureana R; Pasqualone G; Steffan A; Gentile M; Zucchetto A; Gattei V
Hematol Oncol; 2021 Dec; 39(5):712-714. PubMed ID: 34462939
[No Abstract] [Full Text] [Related]
3. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
Roeker LE; Knorr DA; Thompson MC; Nivar M; Lebowitz S; Peters N; Deonarine I; Momotaj S; Sharan S; Chanlatte V; Hampton B; Butala L; Amato L; Richford A; Lunkenheimer J; Battiato K; Laudati C; Mato AR
Leukemia; 2021 Sep; 35(9):2703-2705. PubMed ID: 33986431
[No Abstract] [Full Text] [Related]
4. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
Parry H; McIlroy G; Bruton R; Ali M; Stephens C; Damery S; Otter A; McSkeane T; Rolfe H; Faustini S; Wall N; Hillmen P; Pratt G; Paneesha S; Zuo J; Richter A; Moss P
Blood Cancer J; 2021 Jul; 11(7):136. PubMed ID: 34330895
[TBL] [Abstract][Full Text] [Related]
5. mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Montserrat E
Eur J Haematol; 2022 Mar; 108(3):264-267. PubMed ID: 34856031
[No Abstract] [Full Text] [Related]
6. Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Sällberg Chen M; Zain R; Hansson L; Österborg A
Leukemia; 2022 Feb; 36(2):476-481. PubMed ID: 34564699
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
[TBL] [Abstract][Full Text] [Related]
8. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
[No Abstract] [Full Text] [Related]
9. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.
Avanzato VA; Matson MJ; Seifert SN; Pryce R; Williamson BN; Anzick SL; Barbian K; Judson SD; Fischer ER; Martens C; Bowden TA; de Wit E; Riedo FX; Munster VJ
Cell; 2020 Dec; 183(7):1901-1912.e9. PubMed ID: 33248470
[TBL] [Abstract][Full Text] [Related]
10. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
[TBL] [Abstract][Full Text] [Related]
12. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
[TBL] [Abstract][Full Text] [Related]
13. Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
Fox TA; Kirkwood AA; Enfield L; O'Reilly M; Arulogun S; D'Sa S; O'Nions J; Kavi J; Vitsaras E; Townsend W; Burns SO; Gohil SH; Cwynarski K; Thomson KJ; Noursadeghi M; Heyderman RS; Rampling T; Ardeshna KM; McCoy LE; Morris EC
Br J Haematol; 2021 Dec; 195(5):706-709. PubMed ID: 34545952
[No Abstract] [Full Text] [Related]
14. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
15. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
16. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.
Roeker LE; Knorr DA; Pessin MS; Ramanathan LV; Thompson MC; Leslie LA; Zelenetz AD; Mato AR
Leukemia; 2020 Nov; 34(11):3047-3049. PubMed ID: 32855439
[No Abstract] [Full Text] [Related]
17. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
18. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.
Pimpinelli F; Marchesi F; Piaggio G; Giannarelli D; Papa E; Falcucci P; Spadea A; Pontone M; Di Martino S; Laquintana V; La Malfa A; Di Domenico EG; Di Bella O; Falzone G; Ensoli F; Vujovic B; Morrone A; Ciliberto G; Mengarelli A
J Hematol Oncol; 2021 Jul; 14(1):119. PubMed ID: 34325728
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
[TBL] [Abstract][Full Text] [Related]
20. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
Molica S; Tam C; Polliack A
Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
